Making a Global Impact
From FDA and EMA qualifications to giving patient advocates a voice, C-Path makes a global impact across dozens of therapeutic areas.
Regulatory Successes

C-Path’s Regulatory Endorsements
COA Qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDSS)
FDA and EMA Letters of Support for Two Kidney Biomarkers
FDA and EMA Qualification of C-Path’s Early Alzheimer’s Disease: Developing Drugs for Treatment
FDA. EMA and PMDA Qualifications for Seven Preclinical Safety Biomarkers
EMA Qualifies ‘Hollow Fiber System’ for Anti-Tuberculosis Drug Development
PKDOC Secures Qualification for Enrichment Biomarker in ADPKD
FDA and EMA Letters of Support for Two Kidney Biomarkers
FDA and EMA Qualification of C-Path’s Early Alzheimer’s Disease: Developing Drugs for Treatment
FDA. EMA and PMDA Qualifications for Seven Preclinical Safety Biomarkers
EMA Qualifies ‘Hollow Fiber System’ for Anti-Tuberculosis Drug Development
